...
机译:成功的Lenalidomide治疗在高风险髓细胞增强综合征中的种系DDX41 DDX41突变
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of Clinical Cancer GeneticsThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
机译:成功的Lenalidomide治疗在高风险髓细胞增强综合征中的种系DDX41 DDX41突变
机译:Lenalidomide治疗较低的风险骨髓增强综合征 - 捷克血液中心的经验。 (促红外生物素+/-泼尼松在耐火或复发患者中的阳性作用)
机译:体细胞突变对人参醛植入较低风险的反应的影响(5Q)髓细胞增强综合征患者
机译:RAS基因突变在急性髓性白血病和髓细胞增强综合征中:荟萃分析其发生和预后相关性
机译:骨髓增生异常综合征相关的SRSF2 P95突变的表征。
机译:来那度胺治疗似乎并没有增加5q缺失的低危骨髓增生异常综合征进展的风险。法国法语国家集团的比较分析
机译:体细胞突变对人参醛植入较低风险的反应的影响(5Q)髓细胞增强综合征患者